Marks’ Resignation Is a ‘Blow for Biotech Industry,’ Says RBC Analyst as Biotech Stocks Fall
Biotech stocks took a hit after the sudden resignation of Dr. Peter Marks, head of the FDA’s Center for Biologics Evaluation ...
Sarepta price target lowered to $179 from $210 at BofA
BofA lowered the firm’s price target on Sarepta (SRPT) to $179 from $210 and keeps a Buy rating on the shares. Following the news of the departure of Peter Marks from the FDA’s Center for Biologics ...
Market Inference5h
Sarepta Therapeutics – Assessing Turnaround Potential
Pharmaceutical company Sarepta Therapeutics is taking Wall Street by surprise today, falling to $64.75 and marking a -8.0% ...